These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35395499)

  • 1. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
    Strohbehn GW; Cooperrider JH; Yang D; Fendrick AM; Ratain MJ; Zaric GS
    Value Health Reg Issues; 2022 Sep; 31():34-38. PubMed ID: 35395499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.
    Yu JS; Chin L; Oh J; Farias J
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1028-1040. PubMed ID: 28944733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
    Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
    J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
    Kim AE; Choi DH; Chang J; Kim SH
    Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
    Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
    Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
    Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.
    Carlson JJ; Gries KS; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Jun; 12(3):231-8. PubMed ID: 24664994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review.
    Chen Y; Carlson JJ
    J Manag Care Spec Pharm; 2022 Jan; 28(1):78-83. PubMed ID: 34949115
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib.
    Zheng J; Yu Y; Durairaj C; Diéras V; Finn RS; Wang DD
    Target Oncol; 2021 Jan; 16(1):69-76. PubMed ID: 33211314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
    Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
    Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China.
    Liu C; Li T; Tao Z; Cao J; Wang L; Zhang J; Wang B; Hu X
    Med Sci Monit; 2020 Nov; 26():e927187. PubMed ID: 33250509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
    Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
    N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
    Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
    Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.